ATOS 1.3 (+0%)
US04962H5063BiotechnologyBiotechnology

Atossa Therapeutics (ATOS) Stock Highlights

1.3 | +0%
2024-06-03 03:45:05
Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The companys drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Statistics

Range Today
1.29 1.35
Volume Today 955.5K
Range 1 Year
0.62 2.31
Volume 1 Year 229.26M
Range 3 Year
0.5 9.8
Volume 3 Year 2.21B
Range 10 Year
0.5 477
Volume 10 Year 4.83B

Highlights

Market Capitalization 163.48M (small)
Floating Shares 117.91M
Current Price 1.3
Price To Earnings -5.42
Price To Book 1.9
Earnings Per Share -0.24
Payout Ratio 0%

Performance

Latest 0%
1 Month -13.91%
3 Months +31.31%
6 Months +78.08%
1 Year +35.42%
3 Years -60.84%
5 Years -50.57%
10 Years -99.52%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.